Moderna, Inc. (MRNA) stock
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30508% above fair value
$196.79−10.01 (-4.84%)
Close on Nov 18, 2026Market cap $78.57BP/E –Yield –
Moderna price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Moderna's price to book ratio was 14.7× on Nov 11, 2026, against 1.1× a year earlier. Over the last 5 years it ranged from 1.0× to 14.7×, with a median of 2.6×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 14.7× | +13.4 |
| 2025 | Dec 31, 2025 | 1.2× | −0.1 |
| 2024 | Dec 31, 2024 | 1.3× | −1.5 |
| 2023 | Dec 29, 2023 | 2.8× | −1.0 |
| 2022 | Dec 30, 2022 | 3.9× | −6.3 |
| 2021 | Dec 31, 2021 | 10.2× | −4.8 |
| 2020 | Dec 31, 2020 | 15.0× | +9.8 |
| 2019 | Dec 31, 2019 | 5.2× | – |
See a number that looks wrong?